Anne Li April 23rd, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) have committed £2.5 million in collaboration with the National Cancer Institute(NCI) in the US to tackle one of the toughest challenges in cancer that has thwarted researchers for more than 30 years. Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-04-19-crt-pioneer-fund-cancer-research-uk-and-nci-collaborate-to-boost-research-against-the-undruggable
